AR054726A1 - 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2- fenil- indoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
AR054726A1
AR054726A1 ARP060100278A ARP060100278A AR054726A1 AR 054726 A1 AR054726 A1 AR 054726A1 AR P060100278 A ARP060100278 A AR P060100278A AR P060100278 A ARP060100278 A AR P060100278A AR 054726 A1 AR054726 A1 AR 054726A1
Authority
AR
Argentina
Prior art keywords
alkynyl
alkenyl
alkyl
optionally substituted
substituent groups
Prior art date
Application number
ARP060100278A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR054726A1 publication Critical patent/AR054726A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a una de sus sales, hidratos o solvatos farmacéuticamente aceptables, uno de sus profármacos farmacéuticamente aceptables, o una sal, hidrato o solvato del profármaco farmacéuticamente aceptable, una composicion farmacéutica que comprende una cantidad terapéuticamente eficaz de uno o más compuestos segun al formula (1), en mezcla con un vehículo farmacéuticamente aceptable, un método para tratar a un paciente que sufre un trastorno mediado por la PGD2 incluyendo, pero sin limitarse a ellas, enfermedades alérgicas (tales como rinitis alérgica, conjuntivitis alérgica, dermatitis atopica, asma bronquial y alergia a los alimentos), mastocitosis sistémica, trastornos acompanados de la activacion sistemática de los mastocitos, shock anafiláctico, broncoconstriccion, bronquitis, urticaria, eczema, enfermedades acompanadas de prurito (tales como dermatitis atopica y urticaria), enfermedades (tales como cataratas, desprendimiento de retina, inflamacion, infeccion y trastornos del sueno) que se generan de forma secundaria como resultado de la conducta acompanadas de prurito (tales como escarificaciones y contusiones), inflamacion, enfermedades pulmonares obstructivas cronicas, lesiones por reperfusion isquémica, accidente cerebrovascular, artritis reumatoide cronica, pleuresía, colitis ulcerosa y similares, administrando a dicho paciente una cantidad terapéuticamente eficaz de un compuesto segun la formula (1). Reivindicacion 1: Un compuesto de la formula (1), en la que: R es R1SO2-, R1SO-, R1S-, -R1CO-, R8-C(=O)-NH-, o R8-SO2-NH-; R1 es alquilo, alquenilo, o alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos; cicloalquilo, cicloalquenilo, arilo, heteroarilo, heterociclilo, heterociclenilo, o alcarilo multicíclico, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes anulares; o -NR'R'' cuando R es R1SO2- o R1CO-; R' es hidrogeno; arilo, heteroarilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, o alcarilo multicíclico, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes anulares; o alquilo, alquenilo o alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos; R'' es hidrogeno, alquilo, alquenilo o alquinilo; R2 es hidrogeno, halo, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, alcoxi, alqueniloxi o alquiniloxi; R3 es acilo, ciano, carboxi, ácido bioisostero, -C(O)-NY1Y2; aroilo o heteroarilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes anulares; alquilo, alquenilo o alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos; o alcoxi, alqueniloxi o alquiniloxi, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos; Y1 e Y2 son cada uno independientemente hidrogeno, alquilsulfonilo, arilsulfonilo, arilamino, heteroarilsulfonilo, heteroarilamino; o alquilo, alquenilo o alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos, R4 es hidrogeno, acilo, aroilo, heteroarilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo heteroarilsulfonilo, heteroarilalquilsulfonilo, -C(O)-NY4Y5, -C(O)-O-Y6; alquilo, alquenilo o alquinilo, cada uno de los cuales está opcionalmente sustituido con arilo, heteroarilo, carboxi, alcoxicarbonilo, aminocarbonilo, alquilaminocarbonilo, dialquilaminocarbonilo, aroilo, heteroaroilo o acilo; o alquilo C2-6, alquenilo o alquinilo, cada uno de los cuales está sustituido con halo, hidroxi, alcoxi, amino, alquilamino o dialquilamino; Y4 e Y5 son cada uno independientemente hidrogeno, alquilo, alquenilo o alquinilo; Y6 es alquilo, alquenilo o alquinilo; R5 es hidrogeno, halo, carboxi, ciano, nitro, hidroxi, alquilo, alquenilo, alquinilo, haloalquilo, haloalquenilo, haloalquinilo, alcoxi, alqueniloxi, alquiniloxi, haloalcoxi, haloalqueniloxi o haloalquiniloxi; R6 y R7 son cada uno independientemente, hidrogeno, alquilo, alquenilo o alquinilo; o R8 es alquilo, alquenilo, o alquinilo, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes alifáticos; o arilo, heteroarilo, cicloalquilo, cicloalquenilo, heterociclilo, heterociclenilo, o alcarilo multicíclico, cada uno de los cuales está opcionalmente sustituido con uno o más grupos sustituyentes anulares; y n es 1 a 6, o 0 cuando R3 es carboxi, ácido bioisostero, o -C(O)-NY1Y2; con la condicion de que cuando R1 es amino, entonces R4 es hidrogeno y n es 1 a 6; o una de sus sales, hidratos o solvatos farmacéuticamente aceptables, uno de sus profármacos farmacéuticamente aceptables, o una sal, hidrato o solvato del profármaco farmacéuticamente aceptable.
ARP060100278A 2005-01-26 2006-01-25 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2 AR054726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64730705P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
AR054726A1 true AR054726A1 (es) 2007-07-11

Family

ID=36282872

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100278A AR054726A1 (es) 2005-01-26 2006-01-25 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20070265278A1 (es)
EP (1) EP1844011A1 (es)
JP (1) JP2008528606A (es)
KR (1) KR20070110277A (es)
CN (1) CN101146770A (es)
AR (1) AR054726A1 (es)
AU (1) AU2006209213A1 (es)
BR (1) BRPI0607079A2 (es)
CA (1) CA2595728A1 (es)
CR (1) CR9214A (es)
DO (1) DOP2006000016A (es)
GT (1) GT200600030A (es)
IL (1) IL184816A0 (es)
MA (1) MA29259B1 (es)
MX (1) MX2007008277A (es)
NO (1) NO20074336L (es)
PA (1) PA8661201A1 (es)
PE (1) PE20060878A1 (es)
RU (1) RU2007132166A (es)
SG (1) SG158918A1 (es)
TN (1) TNSN07251A1 (es)
TW (1) TW200639151A (es)
UY (1) UY29346A1 (es)
WO (1) WO2006081343A1 (es)
ZA (1) ZA200705449B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659055A1 (en) * 2006-07-25 2008-01-31 Sanofi-Aventis 2-phenyl-indoles as prostaglandin d2 receptor antagonists
ES2374321T3 (es) 2006-08-07 2012-02-15 Actelion Pharmaceuticals Ltd. Derivados del ácido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acético.
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
WO2009061730A2 (en) * 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
RU2562255C2 (ru) 2010-03-22 2015-09-10 Актелион Фармасьютиклз Лтд Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2
US8722719B2 (en) * 2010-10-06 2014-05-13 Kureha Corporation Amine compound and use for same
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
EP2548863A1 (en) * 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2762141A4 (en) * 2011-09-29 2015-03-25 Shionogi & Co THERAPEUTIC PHARMACEUTICAL PRODUCT AGAINST ALLERGIC RHINITIS COMPRISING A PGD2 ANTAGONIST AND A HISTAMINE ANTAGONIST
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6168520B2 (ja) * 2013-09-17 2017-07-26 国立大学法人 千葉大学 インドール化合物、ｄｐプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びｄｐプロスタノイド受容体アンタゴニストの使用。
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
MX2020002788A (es) 2017-09-13 2020-09-14 Progenity Inc Biomarcadores de preeclampsia y sistemas y metodos relacionados.
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN113173877B (zh) * 2020-10-30 2023-10-27 江西师范大学 吲哚乙酰基亚氨基砜系列化合物及其制备方法
CN115925606B (zh) * 2023-01-05 2023-10-13 宁夏医科大学 一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950701317A (ko) * 1992-05-08 1995-03-23 오오쓰까 아끼히꼬 인돌 유도체(Indole Derivative)
FR2751966B1 (fr) * 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
JP2004024655A (ja) * 2002-06-27 2004-01-29 Aruze Corp 遊技機
EP1600440A1 (en) * 2003-03-06 2005-11-30 Ono Pharmaceutical Co., Ltd. Indole derivative compounds and drugs containing the compounds as the active ingredient
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US8013006B2 (en) * 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C

Also Published As

Publication number Publication date
TW200639151A (en) 2006-11-16
WO2006081343A1 (en) 2006-08-03
PE20060878A1 (es) 2006-10-18
CR9214A (es) 2007-11-23
EP1844011A1 (en) 2007-10-17
JP2008528606A (ja) 2008-07-31
AU2006209213A1 (en) 2006-08-03
KR20070110277A (ko) 2007-11-16
TNSN07251A1 (en) 2008-12-31
GT200600030A (es) 2006-09-27
US20070265278A1 (en) 2007-11-15
CN101146770A (zh) 2008-03-19
IL184816A0 (en) 2007-12-03
DOP2006000016A (es) 2006-07-31
NO20074336L (no) 2007-10-23
RU2007132166A (ru) 2009-03-10
CA2595728A1 (en) 2006-08-03
UY29346A1 (es) 2006-08-31
MA29259B1 (fr) 2008-02-01
BRPI0607079A2 (pt) 2009-08-04
SG158918A1 (en) 2010-02-26
ZA200705449B (en) 2009-01-28
PA8661201A1 (es) 2006-09-08
MX2007008277A (es) 2007-09-07

Similar Documents

Publication Publication Date Title
AR054726A1 (es) 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2
US9758505B2 (en) 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
ECSP088813A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
AR065874A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20161372A1 (es) Inhibidores de dihidropirrolopiridina de ror-gamma
PE20141010A1 (es) Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
DOP2006000220A (es) Sal de dihidrógeno fosfato de un antagonista del receptor de prostaglandina d2
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR076002A1 (es) Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR086881A1 (es) Derivados de picolinamida como agonistas del receptor cb2
AR075597A1 (es) Derivados de indol como antagonistas de receptores crth2, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del asma y otras enfermedades alergicas .
AR062051A1 (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
JP2019505500A (ja) 哺乳類ヒストンデアセチラーゼ活性の阻害剤として有用な二環式ヒドロキサム酸
CA2900308A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
WO2016016366A1 (en) Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
PE20221916A1 (es) Compuestos quimicos
EP3174861A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3107911A1 (en) Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
Wu et al. Synthesis and antibacterial activity of 2-morpholino-1-propyl-1H-indole-3-substituted acylhydrazone derivatives

Legal Events

Date Code Title Description
FA Abandonment or withdrawal